Impact
Insurance Companies. Why? Because the specific data will enable them to understand the actual usage of high-cost injectable medications, especially those administered outside clinical settings (ie factor medication used to treat hemophilia; costs several hundred thousands to a couple million dollars per patient each year).
Hospital Groups. Why? Because the specific data will enable them to account for precise usage and timing of intravenous administration. Lessens the potential for human error to lead to negative health outcomes and/or legal issues.
Infusion Centers. Why? Because the specific data will enable them to account for precise usage and timing of intravenous administration. Increases the likelihood of insurance reimbursements for their centers (as opposed to competitors)
Military & First Responders. Monitoring the speed and efficiency with which battlefield or event injuries are treated can improve response time and effectiveness, providing critical data on the “golden hour” following an injury or life-threatening incident.
Specialty Pharmacies & Home Health Service Providers Why? Because the specific data will enable them to account for precise usage and timing of intravenous administration. Increases the likelihood of insurance reimbursements for their pharmacies/services (as opposed to competitors).
Pharmaceutical Manufacturers of Injectable Medications. Why? Because the specific data will enable them to account for precise usage and timing of intravenous administration, increasing a patient’s ability to customize their individualized care plan, and increasing an insurance company’s likelihood of putting the drugmaker’s product on their formulary.
Pharmaceutical Manufacturers in Emerging Markets/Developing Nations. Why? Because the specific data will enable them to account for precise usage and timing of intravenous administration, which will be viewed favorably by ministers of health and other government officials who must decide whether or not to purchase injectable medications (such as clotting factor) for their country’s patients.
Hemophilia Treatment Centers & Specialty Clinics. Why? Because the specific data will enable them to account for precise usage and timing of intravenous administration and to check that against bleeding episodes and other negative health outcomes. To date, there is a significant data gap that greatly hampers medical experts to assess a patient’s yearly bleeding patterns with much nuance.